Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer-Reference-Cited by-同舟云学术

Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer

Published:2021-07-19 Issue: Volume: Page:1-9
ISSN:1661-3791
Container-title:Breast Care
language:en
Short-container-title:Breast Care

Author:

Rhiem Kerstin,Auber Bernd,Briest Susanne,Dikow Nicola,Ditsch Nina,Dragicevic Neda,Grill Sabine,Hahnen Eric,Horvath Judit,Jaeger Bernadette,Kast Karin,Kiechle Marion^ORCID,Leinert Elena,Morlot Susanne^ORCID,Püsken Michael^ORCID,Schäfer Dieter,Schott Sarah,Schroeder Christopher,Siebers-Renelt Ulrike,Solbach Christine,Weber-Lassalle Nana,Witzel Isabell^ORCID,Zeder-Göß Christine,Schmutzler Rita K.

Abstract

Background: The German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) has established a multigene panel (TruRisk®) for the analysis of risk genes for familial breast and ovarian cancer. Summary: An interdisciplinary team of experts from the GC-HBOC has evaluated the available data on risk modification in the presence of pathogenic mutations in these genes based on a structured literature search and through a formal consensus process. Key Messages: The goal of this work is to better assess individual disease risk and, on this basis, to derive clinical recommendations for patient counseling and care at the centers of the GC-HBOC from the initial consultation prior to genetic testing to the use of individual risk-adapted preventive/therapeutic measures.

Publisher

S. Karger AG

Subject

Oncology,Surgery

Reference46 articles.

1. Weber-Lassalle N, Hauke J, Ramser J, et al. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Res. 2018 Jan 24;20(1):7.

2. Weber-Lassalle N, Borde J, Weber-Lassalle K, et al. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. Breast Cancer Res. 2019 Apr 29;21(1):55. Published.

3. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–16.

4. Engel C, Fischer C, Zachariae S, et al. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance. Int J Cancer. 2020;146(4):999–1009.

5. Bick U, Engel C, Krug B, et al. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat. 2019;175(1):217–28.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update Mammakarzinom 2023 Teil 3 – Expertenmeinungen zu Brustkrebs in frühen Krankheitsstadien;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2023-12

2. Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies;Geburtshilfe und Frauenheilkunde;2023-09

3. Clinical Impact of Polygenic Risk Score for Breast Cancer Risk Prediction in 382 Individuals with Hereditary Breast and Ovarian Cancer Syndrome;Cancers;2023-08-02

4. Changes in the incidence of early-onset breast cancer in Germany between 2010 and 2022;Breast Cancer Research and Treatment;2023-07-31

5. Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers;Cancers;2023-07-28